SCHEMBL6285536

SCHEMBL6285536

Nc1cccc(NC(=O)Nc2ncc(C3CC3)s2)c1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 13/20 0.67
CDK2 P24941 13/20 0.67
CDK5 Q00535 13/20 0.67
DDX3X O00571 2/20 0.57
CDK5R1 Q15078 1/20 0.46
FBP1 P09467 1/20 0.46
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK13 O15264 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42
MAPK14 Q16539 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282688 0.88 CCNE1 (0.67) CCNE1CDK2CDK5CDK5R1ALDH1A1
SCHEMBL6288023 0.86 CCNE1 (0.66) CCNE1CDK2CDK5ALDH1A1SMN1; SMN2
SCHEMBL6286722 0.86 CCNE1 (0.68) CCNE1CDK2CDK5CDK5R1ALDH1A1
SCHEMBL6281751 0.85 CDK2 (0.90) CCNE1CDK2CDK5CDK5R1ALDH1A1
SCHEMBL6287288 0.83 CCNE1 (0.62) CCNE1CDK2CDK5ALDH1A1SMN1; SMN2
SCHEMBL6283917 0.82 CCNE1 (0.61) CCNE1CDK2CDK5DDX3XALDH1A1
SCHEMBL6285829 0.82 FBP1 (0.65) CCNE1CDK2CDK5DDX3XFBP1
SCHEMBL5780187 0.81 CCNE1 (0.80) CCNE1CDK2CDK5CDK5R1SMN1; SMN2
SCHEMBL6287953 0.81 CCNE1 (0.69) CCNE1CDK2CDK5CDK5R1ALDH1A1
SCHEMBL5782078 0.81 CDK2 (1.00) CCNE1CDK2CDK5CDK5R1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CCNE1 83/4885CDK2 3/4885CDK5 129/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CCNE1 83/4885CDK2 3/4885CDK5 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.